Table 2.
The characteristics of the cohort (IQR = interquartile range)
| Total number of patients | 5 197 | |
|---|---|---|
| Patient months | Overall On ART |
136 672 116 306 (85%) |
| Duration on ART (months) | Median IQR |
19 (10 to 32) |
| Age at starting ART (years) | Median IQR |
37.3 years (32.4 to 42.9) |
| Sex | Female Male |
6 379(59.%) 4 356 (41%) |
| Patient status at end of study period | Active Left the scheme Dead |
2 922 (56%) 1 834 (34%) 421 (8%) |
| Baseline CD4+ cell count | Median IQR |
87 cells/μL (37 to 145) |
| Baseline viral load (log10) | Median IQR |
5.22 (4.73 to 5.63) |
| NNRTI used in first line | Nevirapine Efavirenz |
2 655 (26%) 6 711 (74%) |
| NRTI combination in first line | Zidovudine + lamivudine Stavudine + lamivudineother other |
3 339 (65%) 1 225 (24%) 633 (11%) |
| Duration of CD4+ cell count monitoring before starting ART (months) | Median IQR |
1.2 (0.6 to 2.6) |
| Overall Adherence as measured by monthly pharmacy refill data | Median IQR |
74.4% (38.4 to 92.3) |
IQR=Interquartile Range